Arrowhead Pharmaceuticals is a biotechnology company that develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded in 1989 by R. Bruce Stewart and is headquartered in Pasadena, CA. Specifically, Arrowhead’s therapies utilize gene silencing through triggering the RNA interference mechanism. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.
Arrowhead Pharmaceuticals’ Targeted RNAi Molecule, or TRiM, platform utilizes ligand-mediated delivery and enables tissue-specific targeting in order to develop targeted drug therapies. The TRiM platform currently focuses on tissues within the liver. However, Arrowhead is working to expand the platform’s applications to include tissues in the lungs and tumors.
Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing
February 27, 2020
Pipeline - Arrowhead Pharmaceuticals, Inc.
Science - Arrowhead Pharmaceuticals, Inc.
The Story Of Arrowhead Pharmaceuticals' Adversity Odyssey
April 1, 2020